Compare European CDMOs with EMA-compliant facilities across Germany, Switzerland, Ireland, and the broader EU. Filter by specialization, scale, and regulatory approvals.
926 companies listed
Europe is the second-largest pharma manufacturing region globally, with particular strengths in biologics, API synthesis, and sterile manufacturing. Germany leads in both volume and technological capability, followed by Switzerland (home to major CDMO headquarters), Ireland (a biologics manufacturing hub driven by favorable tax policy), and Italy (strong in API and generics).
EMA regulation provides mutual recognition advantages. A GMP certificate from one EU member state is recognized across the bloc, simplifying multi-market filings. The EMA also maintains Mutual Recognition Agreements (MRAs) with regulators in the US, Canada, Australia, Japan, and other markets, meaning European GMP inspections are often accepted by foreign authorities.
How does pricing compare? European CDMOs typically cost 10-30% more than Asian alternatives but offer shorter lead times for European and US sponsors, stronger IP protection, and established regulatory relationships. For high-value biologics and specialty products, the total cost of quality often favors European manufacturing.
Every country below has its own page with a ranked CDMO list, a country-zoomed facilities map, and the local regulatory picture. Counts are live manufacturing-site totals.
Germany
AXOlabs is an integrated CRO/CDMO specializing in nucleic acid therapeutics (oligonucleotides). Their platform spans from discovery (lead identification and chemistry optimization using bioinformatics-driven design and high-throughput screening) through preclinical safety/PK studies and GLP-compliant bioanalysis to GMP-compliant manufacturing of ASOs, siRNAs, sgRNAs, aptamers, and bioconjugates for clinical phases I-III and initial commercial supply. AXOlabs operates dual-site, globally integrated facilities in Petaluma, California (USA) and Berlin/Kulmbach (Germany), equipped with Cytiva OligoPilot, OligoProcess, and Asahi Kasei THESYS platforms. The company partners with Codexis on enzymatic RNA manufacturing and with Asahi Kasei on oligonucleotide production technologies.
France
Axyntis is the independent leader of the fine chemical sector in France, operating as a CDMO for pharmaceutical APIs and intermediates. Founded in 2007, the group has multiple manufacturing sites in France including Orgapharm (Pithiviers), Centipharm (Grasse), and Steiner (Saint-Marcel). They produce active pharmaceutical ingredients including about 20 generic APIs with regulatory support (DMF and CEP), as well as specialty chemistry intermediates. Axyntis operates under cGMP conditions with quality assurance and regulatory affairs oversight, offering services from laboratory through pilot to industrial production scale, including preparative chromatography and hydrogenation.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.